| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2016) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| ATC: | N03AX23 |
| UNII: | U863JGG2IA |
| InChI Key | MSYKRHVOOPPJKU-BDAKNGLRSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C11H20N2O2 |
| Molecular Weight | 212.29 |
| AlogP | 0.9 |
| Hydrogen Bond Acceptor | 2.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 63.4 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 0.0 |
| Heavy Atoms | 15.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| MODULATOR | Synaptic vesicle glycoprotein 2A modulator |
| Primary Target | |
|---|---|
| synaptic vesicle glycoprotein 2A |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Transferase
|
- | - | - | - | ||
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | -6.98-29.15 | |
|
Transporter
Electrochemical transporter
Vesicular neurotransmitter transporter family
|
- | 1e+16 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Seizures | 4 | D012640 | ClinicalTrials |
| Epilepsy, Absence | 3 | D004832 | ClinicalTrials |
| Unverricht-Lundborg Syndrome | 3 | D020194 | ClinicalTrials |
| Epilepsy, Absence | 3 | D004832 | ClinicalTrials |
| Neuralgia, Postherpetic | 2 | D051474 | ClinicalTrials |
| Spinal Cord Injuries | 1 | D013119 | ClinicalTrials |
| Brain Neoplasms | 1 | D001932 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 357336-20-0 |
| ChEBI | 133013 |
| ChEMBL | CHEMBL607400 |
| DrugBank | DB05541 |
| DrugCentral | 5068 |
| FDA SRS | U863JGG2IA |
| Guide to Pharmacology | 9041 |
| PharmGKB | PA166153491 |
| PubChem | 9837243 |
| SureChEMBL | SCHEMBL122081 |
| ZINC | ZINC000003979899 |